A KFF Health News analysis republished by The Good Men Project picks apart four phrases commonly used to sell experimental peptides, at the moment federal policy on those compounds is actively in play.

The compounds in question include BPC-157, a peptide isolated by Croatian scientists from gastric juices in the stomach lining and widely sold through longevity and "body optimization" clinics. None of the six experimental peptides the FDA is currently reviewing have been approved for safety or effectiveness.

What is on the docket

On October 14 a temporary "access policy" appeared on a White House docket proposing to let licensed pharmacies make and sell certain unapproved peptides directly to people. FDA scientists had advised against it at a July meeting, warning the drugs had not been adequately vetted in clinical trials.

An FDA advisory panel voted the other way. Many panel members are new appointees with financial stakes in the peptide industry, and one of them, Haleem Mohammed, is chief medical officer of a men's clinic that sells peptides. HHS spokesperson Emily Hilliard told KFF every committee member satisfies the agency's ethics requirements.

The four phrases

The claims KFF singles out are that peptides are not drugs, that they are safe because they are natural, that they treat specific conditions, and that pharmaceutical companies ignore them because they cannot be patented. That last one is the easiest to check: hundreds of peptide patents sit in the USPTO database, and a patent on an early BPC-157 formulation is for sale.

"One cannot obtain a patent on the natural thing itself," said Jacob Sherkow, a biotechnology law professor at the University of Illinois Urbana-Champaign, "but if you slightly modify it, link it to something that allows me to inject it, formulate it to be more stable, all of that stuff is patentable."

Where the evidence stops

The trial record is thin enough to be worth stating plainly. A 2005 summary of a small BPC-157 trial in inflammatory bowel disease was called "inadequate" by FDA reviewers, and a separate study reporting knee pain relief in 14 of 16 patients had no control group at all.

A 2025 review of BPC-157 for musculoskeletal injuries said it should be "approached with caution" given the lack of evidence. Co-author Flynn McGuire, a rehabilitation doctor at the University of Utah, said he will not prescribe it until quality studies exist.

Bottom line

Stanford peptide scientist Katrin Svensson, whose own lab works on several peptides, put the gap simply: she is excited about them too, but "you need to show they're not harmful." Researchers quoted by KFF warn that easing access may make those studies less likely, not more, since compounding pharmacies would no longer need approval to sell.